Wells Fargo & Company Boosts Agilent Technologies (NYSE:A) Price Target to $175.00

Agilent Technologies (NYSE:A) had its price objective lifted by investment analysts at Wells Fargo & Company from $150.00 to $175.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has an “overweight” rating on the medical research company’s stock. Wells Fargo & Company‘s price target would suggest a potential upside of 10.36% from the stock’s current price.

A number of other equities research analysts also recently issued reports on A. Rothschild Redb raised shares of Agilent Technologies to a “strong-buy” rating in a report on Wednesday, October 8th. UBS Group upgraded shares of Agilent Technologies from a “neutral” rating to a “buy” rating and increased their target price for the stock from $130.00 to $170.00 in a research note on Wednesday, October 8th. Evercore ISI raised their price target on shares of Agilent Technologies from $128.00 to $140.00 and gave the company an “in-line” rating in a report on Tuesday, October 7th. Weiss Ratings restated a “hold (c)” rating on shares of Agilent Technologies in a research report on Wednesday, October 8th. Finally, TD Cowen increased their price objective on Agilent Technologies from $150.00 to $162.00 and gave the stock a “buy” rating in a research report on Tuesday, October 14th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $156.77.

Agilent Technologies Stock Performance

Shares of NYSE A traded up $4.97 during trading on Tuesday, reaching $158.57. 1,005,642 shares of the stock traded hands, compared to its average volume of 1,897,296. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.71. The stock has a market capitalization of $44.95 billion, a P/E ratio of 37.24, a price-to-earnings-growth ratio of 4.67 and a beta of 1.29. Agilent Technologies has a 52-week low of $96.43 and a 52-week high of $158.63. The company has a 50-day moving average of $140.20 and a 200-day moving average of $125.68.

Agilent Technologies (NYSE:A) last released its quarterly earnings data on Monday, November 24th. The medical research company reported $1.59 EPS for the quarter, beating the consensus estimate of $1.58 by $0.01. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The business had revenue of $1.86 billion for the quarter, compared to the consensus estimate of $1.83 billion. During the same period in the prior year, the firm earned $1.46 earnings per share. The company’s revenue was up 9.4% compared to the same quarter last year. Agilent Technologies has set its Q1 2026 guidance at 1.350-1.380 EPS. FY 2026 guidance at 5.860-6.000 EPS. Analysts forecast that Agilent Technologies will post 5.58 EPS for the current fiscal year.

Insider Buying and Selling

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 12,490 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $150.00, for a total transaction of $1,873,500.00. Following the sale, the chief executive officer owned 33,448 shares in the company, valued at $5,017,200. This trade represents a 27.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.26% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Capital A Wealth Management LLC boosted its stake in shares of Agilent Technologies by 10,600.0% in the 2nd quarter. Capital A Wealth Management LLC now owns 214 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 212 shares in the last quarter. Davis Capital Management purchased a new stake in Agilent Technologies during the third quarter valued at about $28,000. Stone House Investment Management LLC purchased a new stake in Agilent Technologies during the first quarter valued at about $30,000. Physician Wealth Advisors Inc. grew its stake in shares of Agilent Technologies by 490.0% during the third quarter. Physician Wealth Advisors Inc. now owns 236 shares of the medical research company’s stock valued at $30,000 after buying an additional 196 shares during the last quarter. Finally, Ransom Advisory Ltd purchased a new position in shares of Agilent Technologies in the first quarter worth about $32,000. 87.41% of the stock is owned by hedge funds and other institutional investors.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.